There is always the chance the item you purchased does not live up to your expectations, or, you may want to return the gifts ...

(Radiology)Multiple recent market withdrawals of drugs that received FDA accelerated approvals have raised concern about the ...

After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to hospitalized patients. However, the ...

Researchers at the University of Ottawa have made a significant advancement in the diagnosis of heart disease, according to a study published in Nature Nanotechnology.

Oxbryta came to market in 2019, a few days after Novartis' injectable anti-P-selectin antibody Adakveo (crizanlizumab), which is also tipped for blockbuster sales but like Oxbryta has suffered ...

This study presents P-selectin-targeting mimic ligand-coated NIR-II-interacting gold nanoparticle-based superclusters as in vivo contrast agents for enhanced imaging of intravascular inflammation ...

With another failure of E-selectin antagonist uproleselan on the books, Glycomimetics Inc. signed an acquisition agreement with privately held, solid tumor-focused Crescent Biopharma Inc., and a ...

This study presents P-selectin-targeting mimic ligand-coated NIR-II-interacting gold nanoparticle-based superclusters as in vivo contrast agents for enhanced imaging of intravascular inflammation ...

With another failure of E-selectin antagonist uproleselan on the books, Glycomimetics Inc. signed an acquisition agreement with privately held, solid tumor-focused Crescent Biopharma Inc., and a ...

C-reactive protein, interleukin (IL)-6, IL-8, IL-10, monocyte chemoattractant protein-1, soluble tumor necrosis factor receptor I, soluble form suppression of tumorigenicity 2, matrix ...

PRESS RELEASEAB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE ...